Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed Price. Currency in AUD
0.00300.0000 (0.00%)
At close: 02:17PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0030
Open0.0030
Bid0.0020 x 10000000
Ask0.0030 x 249000000
Day's Range0.0030 - 0.0030
52 Week Range0.0020 - 0.0080
Volume4,949,983
Avg. Volume13,897,234
Market Cap34.625M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateFeb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GTG.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Back-to-back Studies Validate geneType Breast Cancer Risk Test

      MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research. Highlights: 2nd published peer reviewed paper in the last month supporting the use of geneTyp

    • GlobeNewswire

      New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

      MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.The

    • GlobeNewswire

      Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

      MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American Depositary Shares (“ADSs”), each representing six hundred (600) ordinary shares

    Advertisement
    Advertisement